Publisher： Adis International
ISSN： 1173-5503
Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.516, 2006-01, pp. : 9-9
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Standard chemo plus docetaxel does not compromise QOL
Inpharma, Vol. 1, Iss. 1563, 2006-01 ,pp. :
Access to resources
Recommend
Docetaxel added to standard chemotherapy does not compromise QOL
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 515, 2006-01 ,pp. :
Sorafenib: In Advanced Renal Cancer
By McKeage Kate Wagstaff Antona J.
Drugs, Vol. 67, Iss. 3, 2007-01 ,pp. :
Sorafenib for the treatment of renal cancer
Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 3, 2012-02 ,pp. :
Superior QOL with sunitinib in renal cancer
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 560, 2008-01 ,pp. :